# Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment

> **NCT01395875** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2849 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)
- **DRUG:** Anticholinergics (AC)

## Key facts

- **NCT ID:** NCT01395875
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-04
- **Final completion:** 2011-06
- **Target enrollment:** 2849 (ACTUAL)
- **Last updated:** 2017-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01395875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01395875, "Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01395875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*